BioCentury
ARTICLE | Company News

Biogen hematology spinout Bioverativ launches

February 2, 2017 12:05 AM UTC

Biogen Inc. (NASDAQ:BIIB) spun out its hematology business into Bioverativ Inc. (NASDAQ:BIVV) as a standalone public company. Bioverativ's two marketed drugs, Eloctate efmoroctocog alfa for hemophilia A and Alprolix eftrenonacog alfa for hemophilia B, generated a combined $888 million in 2016 revenues.

The newco also has a preclinical pipeline of at least seven candidates in non-malignant hematology indications. The company expects to begin a clinical study next half of the most advanced program, BIVV 001, to treat hemophilia A. Designed as a once-weekly or less frequently dosed prophylactic, BIVV 001 is a long-acting recombinant fusion protein that uses XTEN polypeptide technology as well as the Fc domain of human IgG1 attached to Factor VIII and von Willebrand factor (vWF)...

BCIQ Company Profiles

Biogen Inc.

Bioverativ Inc.